← All trials
NCT03507829
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 21, 2012
- Primary completion
- May 22, 2018
- Completion date
- May 22, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 263
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Medical University of ViennaLead sponsor
- Medical University of ViennaReponsible party - principal investigator
- Medical University of ViennaOverall official - principal investigator
- Medical University of GrazCollaborator
- Universidad Autonoma de BarcelonaCollaborator
- Humboldt UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.